Hologic, Inc.  

(Public, NASDAQ:HOLX)   Watch this stock  
Find more results for HOLX
35.05
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 22.70 - 35.35
Open     -
Vol / Avg. 0.00/1.60M
Mkt cap 9.85B
P/E 85.62
Div/yield     -
EPS 0.41
Shares 280.97M
Beta 1.27
Inst. own 98%
Jul 28, 2015
Q3 2015 Hologic Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
May 19, 2015
Hologic Inc at UBS Global Healthcare Conference
May 12, 2015
Hologic Inc at Bank of America Merrill Lynch Health Care Conference
Apr 29, 2015
Q2 2015 Hologic Inc Earnings Call
Apr 29, 2015
Q2 2015 Hologic Inc Earnings Release
Mar 10, 2015
Hologic Inc at Barclays Healthcare Conference - Webcast
Mar 4, 2015
Hologic Inc at Cowen Health Care Conference - Webcast
Mar 3, 2015
Hologic Inc Annual Shareholders Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 7.29% 0.68%
Operating margin 16.75% 10.76%
EBITD margin - 34.15%
Return on average assets 2.38% 0.20%
Return on average equity 8.98% 0.86%
Employees 5,351 -
CDP Score - -

Address

35 Crosby Dr
BEDFORD, MA 01730-1450
United States - Map
+1-781-9997300 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Company’s business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.

Officers and directors

David R. LaVance Jr. Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Stephen P. MacMillan President, Chief Executive Officer, Director
Age: 51
Bio & Compensation  - Reuters
Robert W. McMahon Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Eric Compton Chief Operating Officer
Bio & Compensation  - Reuters
Jay A. Stein Chairman Emeritus, Senior Vice President & Chief Technical Officer
Age: 71
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Claus Egstrand Senior Vice President, General Manager - International
Bio & Compensation  - Reuters
Roger D. Mills Group Senior Vice President, General Manager - Service and Operations
Age: 58
Bio & Compensation  - Reuters
Allison Bebo Senior Vice President - Human Resources
Bio & Compensation  - Reuters
David P. Harding Senior Vice President - Corporate Strategy
Age: 49
Bio & Compensation  - Reuters
John Griffin General Counsel
Bio & Compensation  - Reuters